{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:04:05Z","timestamp":1790255045774,"version":"4.1.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA217883"],"award-info":[{"award-number":["U01 CA217883"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA282109"],"award-info":[{"award-number":["U01 CA282109"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA214428"],"award-info":[{"award-number":["R01 CA214428"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SEngine Precision Medicine"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Biliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid\u2013based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments\u2013certified PARIS assay. Despite most organoids being from late-stage disease, 24\/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR\/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with known genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFR-BICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and &amp;gt;8-month survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0792","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:37:06Z","timestamp":1786383426000},"page":"2026-2038","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>Ex Vivo<\/i>\n                    Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-7706","authenticated-orcid":false,"given":"Annie Blair","family":"Richardson","sequence":"first","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7474-9740","authenticated-orcid":false,"given":"Payel","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6731-3954","authenticated-orcid":false,"given":"Rachele","family":"Rosati","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-1999","authenticated-orcid":false,"given":"Alex","family":"Rajewski","sequence":"additional","affiliation":[{"name":"2Tempus AI, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7880-0758","authenticated-orcid":false,"given":"Robert L.","family":"Diaz","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0492-3063","authenticated-orcid":false,"given":"Lauren R.","family":"Appleyard","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8610-6645","authenticated-orcid":false,"given":"Shalini","family":"Pereira","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-9829","authenticated-orcid":false,"given":"Brady","family":"Bernard","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."},{"name":"3Providence Cancer Institute, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-0941","authenticated-orcid":false,"given":"Milind M.","family":"Javle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-8802","authenticated-orcid":false,"given":"Gentry G.","family":"King","sequence":"additional","affiliation":[{"name":"5Department of Gastrointestinal Medical Oncology, University of Washington School of Medicine, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-8128","authenticated-orcid":false,"given":"Adam","family":"Diehl","sequence":"additional","affiliation":[{"name":"5Department of Gastrointestinal Medical Oncology, University of Washington School of Medicine, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-4017","authenticated-orcid":false,"given":"William Proctor","family":"Harris","sequence":"additional","affiliation":[{"name":"5Department of Gastrointestinal Medical Oncology, University of Washington School of Medicine, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-3038","authenticated-orcid":false,"given":"Sameek","family":"Roychowdhury","sequence":"additional","affiliation":[{"name":"6Ohio State University Comprehensive Cancer Care Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-8452","authenticated-orcid":false,"given":"Christopher J.","family":"Kemp","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/007ps6h72","id-type":"ROR","asserted-by":"publisher"}],"name":"Fred Hutchinson Cancer Center 7 Human Biology Division, , Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4682-9731","authenticated-orcid":false,"given":"Carla","family":"Grandori","sequence":"additional","affiliation":[{"name":"1Cure First, Bothell, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026092408313695000_bib1","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.ejca.2015.07.034","article-title":"Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999\u20132007: results of EUROCARE-5","volume":"51","author":"Lepage","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026092408313695000_bib2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026092408313695000_bib3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092408313695000_bib4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026092408313695000_bib5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States","volume":"16","author":"Mukkamalla","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2026092408313695000_bib6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026092408313695000_bib7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026092408313695000_bib8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"2026092408313695000_bib9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026092408313695000_bib10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092408313695000_bib11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092408313695000_bib12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026092408313695000_bib13","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"2026092408313695000_bib14","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2026092408313695000_bib15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2026092408313695000_bib16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"2026092408313695000_bib17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092408313695000_bib18","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"2026092408313695000_bib19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026092408313695000_bib20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized in vitro and in vivo cancer models to guide precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"2026092408313695000_bib21","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1200\/jco.2020.38.15_suppl.3630","article-title":"Predictive value of a CLIA approved organoid based drug sensitivity test","volume":"38","author":"Margossian","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092408313695000_bib22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026092408313695000_bib23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41698-023-00379-8","article-title":"Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing","volume":"7","author":"Gray","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026092408313695000_bib24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026092408313695000_bib25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"Acanda De La Rocha","year":"2024","journal-title":"Nat Med"},{"key":"2026092408313695000_bib26","doi-asserted-by":"publisher","first-page":"101277","DOI":"10.1016\/j.xcrm.2023.101277","article-title":"Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application","volume":"4","author":"Ren","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026092408313695000_bib27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2021.01.047","article-title":"Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers","volume":"148","author":"Shiihara","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026092408313695000_bib28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2026092408313695000_bib29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2026092408313695000_bib30","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026092408313695000_bib31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2026092408313695000_bib32","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2026092408313695000_bib33","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","article-title":"Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR","volume":"10","author":"Yang","year":"2015","journal-title":"Nat Protoc"},{"key":"2026092408313695000_bib34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"2026092408313695000_bib35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann Oncol"},{"key":"2026092408313695000_bib36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"2026092408313695000_bib37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"2026092408313695000_bib38","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/ijms21093214","article-title":"Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in urothelial cancers with FGFR3 alterations","volume":"21","author":"Lima","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026092408313695000_bib39","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.1073\/pnas.1905239116","article-title":"Repurposing dasatinib for diffuse large B cell lymphoma","volume":"116","author":"Scuoppo","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092408313695000_bib40","doi-asserted-by":"publisher","first-page":"eadj7685","DOI":"10.1126\/scitranslmed.adj7685","article-title":"SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma","volume":"16","author":"Luk","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026092408313695000_bib41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"2026092408313695000_bib42","doi-asserted-by":"publisher","first-page":"e2100489","DOI":"10.1200\/PO.21.00489","article-title":"Complete remission of widely metastatic human epidermal growth factor receptor 2-amplified pancreatic adenocarcinoma after precision immune and targeted therapy with description of sequencing and organoid correlates","volume":"7","author":"King","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0792\/3820489\/crc-25-0792.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/2026\/3826065\/crc-25-0792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/2026\/3826065\/crc-25-0792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:31:51Z","timestamp":1790253111000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/2026\/787738\/Ex-Vivo-Tumor-Derived-Organoid-Pharmacotyping"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0792","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8684414","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33985503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33985500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33985497","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395309","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395306","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395327","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33985494","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33985491","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395303","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395324","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395300","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33395312","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}